Johnson & Johnson names VP, investor relations Johnson & Johnson appointed Jessica Moore to VP of investor relations for Johnson & Johnson. Moore reports to Joseph Wolk, executive VP and […]
Protagonist Therapeutics Inc. chose Scott Plevy, M.D., to be executive VP and therapeutic head, Gastroenterology.
Anocca AB, a leader in unlocking the potential of T-cell immunotherapy to deliver transformative therapeutics, chose Jacob Michlewicz to be chief financial officer.
The board of directors for Oncopeptides AB, a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, tapped Jakob Lindberg as CEO of Oncopeptides.
Reflecting the success of Biorchestra’s research and development programs and anticipating its international expansion and entry into clinical development, the biotech company – focused on the identification of novel targets in neurodegenerative diseases using RNA-based therapeutics – appointed Dr. Louis St.L. O’Dea as its first chief medical officer.
Advanz Pharma Corp. Limited, a specialty pharmaceutical company with a strategic focus on complex medicines in Europe, made several changes in senior leadership roles as it enters the next phase of its growth journey.
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, appointed Zack McGahey as chief operating officer.
Provention Bio Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, appointed Jan Hillson, M.D., as senior VP of Clinical Development.
Blue Water Vaccines Inc., a biopharmaceutical company, named Dr. Ronald R. Cobb its head of Science and Discovery.
Amphista Therapeutics, a leader in next-generation targeted protein degradation approaches, made Beverley Carr the company’s chief business officer.
